These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
279 related items for PubMed ID: 20395439
1. 2p24 Gain region harboring MYCN gene compared with MYCN amplified and nonamplified neuroblastoma: biological and clinical characteristics. Jeison M, Ash S, Halevy-Berko G, Mardoukh J, Luria D, Avigad S, Feinberg-Gorenshtein G, Goshen Y, Hertzel G, Kapelushnik J, Ben Barak A, Attias D, Steinberg R, Stein J, Stark B, Yaniv I. Am J Pathol; 2010 Jun; 176(6):2616-25. PubMed ID: 20395439 [Abstract] [Full Text] [Related]
2. The genetic and clinical significance of MYCN gain as detected by FISH in neuroblastoma. Souzaki R, Tajiri T, Teshiba R, Higashi M, Kinoshita Y, Tanaka S, Taguchi T. Pediatr Surg Int; 2011 Mar; 27(3):231-6. PubMed ID: 21046119 [Abstract] [Full Text] [Related]
4. Copy number gain of MYCN gene is a recurrent genetic aberration and favorable prognostic factor in Chinese pediatric neuroblastoma patients. Wang M, Zhou C, Cai R, Li Y, Gong L. Diagn Pathol; 2013 Jan 15; 8():5. PubMed ID: 23320395 [Abstract] [Full Text] [Related]
10. Quantitative real-time PCR for quick simultaneous determination of therapy-stratifying markers MYCN amplification, deletion 1p and 11q. Boensch M, Oberthuer A, Fischer M, Skowron M, Oestreich J, Berthold F, Spitz R. Diagn Mol Pathol; 2005 Sep 15; 14(3):177-82. PubMed ID: 16106200 [Abstract] [Full Text] [Related]
11. Concomitant DDX1 and MYCN gain in neuroblastoma. Defferrari R, Tonini GP, Conte M, Papio F, Sementa AR, Valent A, Schena F, Perri P, Mazzocco K. Cancer Lett; 2007 Oct 18; 256(1):56-63. PubMed ID: 17611020 [Abstract] [Full Text] [Related]
12. [Methods of detection and prognostic significance of genetic material increase of the short arm of chromosome 2 and a deletion of the short arm of chromosome 1 in patients with neuroblastoma]. Druĭ AE, Tsaur GA, Shorikov EV, Popov AM, Plekhanova OM, Typonogov SN, Savel'ev LI, Tsvirenko SV, Fechina LG. Vopr Onkol; 2013 Oct 18; 59(5):591-8. PubMed ID: 24260886 [Abstract] [Full Text] [Related]
13. Clinical significance of a highly sensitive analysis for gene dosage and the expression level of MYCN in neuroblastoma. Tanaka S, Tajiri T, Noguchi S, Shono K, Ihara K, Hara T, Suita S. J Pediatr Surg; 2004 Jan 18; 39(1):63-8. PubMed ID: 14694373 [Abstract] [Full Text] [Related]
17. Significance of MYCN amplification in international neuroblastoma staging system stage 1 and 2 neuroblastoma: a report from the International Neuroblastoma Risk Group database. Bagatell R, Beck-Popovic M, London WB, Zhang Y, Pearson AD, Matthay KK, Monclair T, Ambros PF, Cohn SL, International Neuroblastoma Risk Group. J Clin Oncol; 2009 Jan 20; 27(3):365-70. PubMed ID: 19047282 [Abstract] [Full Text] [Related]
20. MYCN-status in neuroblastoma: characteristics of tumours showing amplification, gain, and non-amplification. Spitz R, Hero B, Skowron M, Ernestus K, Berthold F. Eur J Cancer; 2004 Dec 20; 40(18):2753-9. PubMed ID: 15571958 [Abstract] [Full Text] [Related] Page: [Next] [New Search]